A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

In pharma, you can take a larger slice of the healthcare pie than your peers, but…

Stocks Extend Rally, Boosted by AI Optimism

Nvidia shares gain, and Microsoft hits a new all-time high as investor enthusiasm for artificial intelligence…

Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion

The deal expands the pharmaceutical company’s portfolio of cancer drugs.

Blockbuster Cancer Treatment Stymied by Supply Chain—for Now

A cell therapy for multiple myeloma promises to be a major blockbuster for J&J and partner…

Big Pharma’s Battle With the Biden Administration Could Have Legs

Wall Street should pay attention as the pharma industry mounts a widening legal campaign against the…

U.S. Would Gain Power to Negotiate Drug Prices Under Manchin-Schumer Bill

Listen to article (2 minutes) A deal between Senate Democrats has revived legislation to significantly expand…

Pharma Is Immune to a Recession, but Not to Washington

One looming problem for the pharma industry is a surprise deal in Washington this week that…

Drugmakers Hope New Heart Drugs Boost Sales, Revive Market

The once lucrative heart-drug market is now poised to make a comeback, but at the cost…

Long Covid is an elusive target for Big Pharma

This is the second column in the three-part Heard on the Street series on Long Covid.…

Big Pharma will not grant bail to battered biotech

Share Market It may have been in a recession, but the Biotechnology Index has fallen off…